Skip to main content
Lincoln Pharmaceuticals ltd. logo

Lincoln Pharmaceuticals ltd. — Investor Relations & Filings

Ticker · LINCOLN ISIN · INE405C01035 LEI · 3358004B6OBJNW8RTT10 BSE.NS Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2025-08-08 Regulatory Filings
Country IN India
Listing BSE.NS LINCOLN

About Lincoln Pharmaceuticals ltd.

https://www.lincolnpharma.com/

Lincoln Pharmaceuticals Ltd. focuses on the development, manufacturing, and marketing of a diverse range of therapeutic formulations. The organization operates advanced manufacturing facilities certified by international standards, including WHO-GMP. Its portfolio spans multiple areas such as anti-infectives, cardiovascular, gastrointestinal, respiratory, and pain management. The company is recognized for its research and development initiatives, particularly in Novel Drug Delivery Systems (NDDS). Key offerings include specialized treatments for tinnitus and a wide array of formulations in dosage forms like tablets, capsules, liquid orals, and injectables. It maintains a significant global footprint, supplying products to numerous international markets across Africa, Southeast Asia, and Latin America, supported by a robust distribution network for its extensive healthcare catalog.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited and BSE Limited, dated August 8, 2025. It references the publication of a newspaper advertisement containing the un-audited financial results (standalone and consolidated) for the quarter ended June 30, 2025. The letter states that the advertisement was published in newspapers and is being submitted for record purposes. There is no detailed financial data or analysis within the document itself, only a notification of the publication of the financial results advertisement. The document is about announcing the publication of financial results, not the results report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and notification rather than a full Interim/Quarterly Report (IR) or Earnings Release (ER).
2025-08-08 English
Updates
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the appointment of a Secretarial Auditor for the company. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The document details the appointment of M/s Ankit Sethi & Associates as Secretarial Auditor for a term of five years starting April 1, 2025, subject to shareholder approval at the upcoming AGM. There are no financial statements, audit opinions, or detailed audit reports included; rather, it is an announcement of an appointment related to corporate governance and compliance. This fits the category of a Regulatory Filing (RNS) as it is a regulatory disclosure about a corporate event that does not fall under other specific categories like Audit Report or Board/Management Information (which usually involves changes in directors or senior management, not auditor appointments). The document length is about 5,222 characters, which is consistent with a detailed regulatory announcement rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-08-07 English
General Updates
Board/Management Information Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the appointment of a Secretarial Auditor. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 30, which pertains to disclosures of material events. The document details the appointment of M/s Ankit Sethi & Associates as the Secretarial Auditor for a term of five years starting April 1, 2025, subject to shareholder approval at the upcoming AGM. The content is an announcement of a board decision and regulatory disclosure rather than a full report or audit document. It does not contain financial statements or detailed audit results but is a notification of a management/board-related change. Therefore, the most appropriate classification is Board/Management Information (MANG).
2025-08-07 English
Change in Director(s)
Board/Management Information Classification · 100% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the re-appointment of several directors and whole-time directors of the company. It references compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including changes in the board or senior management. The document details the re-appointments, terms, and brief profiles of the directors, which is characteristic of announcements about changes in board or management personnel. There is no financial data, earnings information, or report publication mentioned. The document is not a full annual report, audit report, or earnings release. It is clearly an announcement of changes in the company's board of directors and senior management positions. Therefore, the appropriate classification is Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2025-08-07 English
Outcome of Board Meeting
Regulatory Filings
2025-08-07 English
Board Meeting — LINCOLN PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 07-Aug-2025 to consider and approve the Quarterly Unaudited Financial results of the Compan…
Regulatory Filings
2025-07-28 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.